Table 2 Molecular markers of indolent MCL
From: Progress in molecular feature of smoldering mantle cell lymphoma
Ki-67 index ≤ 30% |
CD200 positivity |
No TP53 mutation/deletion |
Lack of SOX11 |
Without rearrangement and overexpression of MYC |
IGHV mutations |
L-MCL16 assay and MCL35 assay |
Unmutated P16 status |
Without/minimal defects of ATM |
No NOTCH1/2 mutation |
Amp 11q gene mutation |
No chr9 deletion |
Several genes that have been valued in recent years (all of them are weakly expressed) |
SPEN |
SMARCA4 (SWI/SNF) |
RANBP2 |
KMT2C |
NSD2 (WHSC1) |
CARD11 |
FBXW7 |
BIRC3 |
KMT2D (MLL2) |
CELSR3 |
TRAF2 |
MAP3K14 |
HNRNPH1 |
Del 9p and /or Del 9q |
SP140 |
PCDH10 |
Genes that lack data |
Kappa light chain restriction |
Almost no incidence of frameshift Bax mutations |
CD34 (−/ ±), CD83(−/ ±) |
No expression of HMG |
PARP1 silencing |
Up-regulation of BACH2 |
Cluster 1 methylation pattern with somatic mutation |
Inhibition of Akt pathway |
No loss of PTEN |
Without overexpression of Mcl-1 |
MicroRNAs upregulation/downregulation |